Loading
A phase 3 trial testing Calderasib in colorectal cancer, now recruiting.
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) is a phase 3 interventional study registered as NCT06997497, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012). Planned enrolment is 477 participants (estimated). The study started in 2025-07-16 and primary completion is expected in 2029-03-28. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Calderasib, Merck & Co. (MSD).
Shares Calderasib, Merck & Co. (MSD).
Shares Calderasib, Merck & Co. (MSD).
Shares Calderasib, Merck & Co. (MSD).
Shares Calderasib, Merck & Co. (MSD).
Shares Calderasib, Merck & Co. (MSD).
Shares KRAS G12C-mutant colorectal cancer, Colorectal cancer.
Shares Calderasib, Merck & Co. (MSD).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/